Skip to main content
Erschienen in: PharmacoEconomics 5/2000

01.05.2000 | Consensus Conference Papers

Assessing Quality in Decision Analytic Cost-Effectiveness Models

A Suggested Framework and Example of Application

verfasst von: Dr Mark Sculpher, Elisabeth Fenwick, Karl Claxton

Erschienen in: PharmacoEconomics | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

Despite the growing use of decision analytic modelling in cost-effectiveness analysis, there is a relatively small literature on what constitutes good practice in decision analysis. The aim of this paper is to consider the concept of ‘validity’ and ‘quality’ in this area of evaluation, and to suggest a framework by which quality can be demonstrated on the part of the analyst and assessed by the reviewer and user.
The paper begins by considering the purpose of cost-effectiveness models and argues that the their role is to identify optimum treatment decisions in the context of uncertainty about future states of the world. The issue of whether such models can be defined as ‘scientific’ is considered. The notion that decision analysis undertaken at time t can only be considered scientific if its outputs closely predict the results of a trial undertaken at time t+1 is rejected as this ignores the need to make decisions on the basis of currently available evidence. Rather, the scientific characteristic of decision models is based on the fact that, in principle at least, such analyses can be falsified by comparison of two states of the world, one where resource allocation decisions are based on formal decision analysis and the other where such decisions are not. This section of the paper also rejects the idea of exact codification of scientific method in general, and of decision analysis in particular, as this risks rejecting potentially valuable models, may discourage the development of novel methods and can distort research priorities. However, the paper argues that it is both possible and necessary to develop a framework for assessing quality in decision models.
Building on earlier work, various dimensions of quality in decision modelling are considered: model structure (disease states, options, time horizon and cycle length); data (identification, incorporation, handling uncertainty); and consistency (internal and external). Within this taxonomy a (nonexhaustive) list of questions about quality is suggested which are illustrated by their application to a specific published model. The paper argues that such a framework can never be prescriptive about every aspect of decision modelling. Rather, it should encourage the analyst to provide an explicit and comprehensive justification of their methods, and allow the user of the model to make an informed judgment about the relevance, coherence and usefulness of the analysis.
Literatur
1.
Zurück zum Zitat Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322–38PubMedCrossRef Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322–38PubMedCrossRef
2.
Zurück zum Zitat Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185–205CrossRef Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185–205CrossRef
3.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996
4.
Zurück zum Zitat Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409PubMedCrossRef Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409PubMedCrossRef
5.
Zurück zum Zitat Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11PubMedCrossRef Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11PubMedCrossRef
6.
Zurück zum Zitat Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27PubMedCrossRef Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27PubMedCrossRef
7.
Zurück zum Zitat Popper KR. The logic of scientific discovery. London: Hitchinson, 1972 Popper KR. The logic of scientific discovery. London: Hitchinson, 1972
8.
Zurück zum Zitat Lakatos I. Falsification and the methodology of scientific research programmes. In: Lakatos I, Musgrave, A, editors. Criticism and the growth of knowledge. Cambridge: Cambridge University Press, 1970: 91–195 Lakatos I. Falsification and the methodology of scientific research programmes. In: Lakatos I, Musgrave, A, editors. Criticism and the growth of knowledge. Cambridge: Cambridge University Press, 1970: 91–195
9.
Zurück zum Zitat Manning R, Claxton K. Experimental and econometric solutions to selection bias. The International Health Economics Association Meeting, 1999 Jun 6–9; Rotterdam Manning R, Claxton K. Experimental and econometric solutions to selection bias. The International Health Economics Association Meeting, 1999 Jun 6–9; Rotterdam
10.
Zurück zum Zitat Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637–48PubMedCrossRef Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637–48PubMedCrossRef
11.
Zurück zum Zitat Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 Suppl.: JS52–64 Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 Suppl.: JS52–64
12.
Zurück zum Zitat Russell B. My philosophical development. London: Routledge, 1959 Russell B. My philosophical development. London: Routledge, 1959
13.
Zurück zum Zitat Sokal A, Bricmont J. Intellectual impostures. London: Profile Books, 1998 Sokal A, Bricmont J. Intellectual impostures. London: Profile Books, 1998
14.
Zurück zum Zitat Feyerabend P. Against method. London: New Left Books, 1975 Feyerabend P. Against method. London: New Left Books, 1975
15.
Zurück zum Zitat Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996; 276: 637–9PubMedCrossRef Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996; 276: 637–9PubMedCrossRef
16.
Zurück zum Zitat Guyatt GH, Sackett DL, Cook DJ. Users’ guides to the medical literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59–63PubMedCrossRef Guyatt GH, Sackett DL, Cook DJ. Users’ guides to the medical literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59–63PubMedCrossRef
18.
Zurück zum Zitat Eddy DM. Technology assessment: the role of mathematical modeling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–53 Eddy DM. Technology assessment: the role of mathematical modeling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–53
19.
Zurück zum Zitat Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131–47PubMedCrossRef Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131–47PubMedCrossRef
20.
Zurück zum Zitat Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press, 1997 Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press, 1997
21.
Zurück zum Zitat Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef
22.
Zurück zum Zitat Nuijten MJC, Starzewski J. Applications of modelling studies. Pharmacoeconomics 1998; 13: 289–91PubMedCrossRef Nuijten MJC, Starzewski J. Applications of modelling studies. Pharmacoeconomics 1998; 13: 289–91PubMedCrossRef
23.
Zurück zum Zitat Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42PubMedCrossRef Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42PubMedCrossRef
24.
Zurück zum Zitat Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345–55PubMed Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345–55PubMed
25.
Zurück zum Zitat Mohr P, Neumann P, Claxton K. Letter to the editor. Am J Manag Care 1998; 4: 1200–1 Mohr P, Neumann P, Claxton K. Letter to the editor. Am J Manag Care 1998; 4: 1200–1
26.
Zurück zum Zitat Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994; 36: 726–36PubMedCrossRef Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994; 36: 726–36PubMedCrossRef
27.
Zurück zum Zitat Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522–3 Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522–3
28.
Zurück zum Zitat Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993 Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993
29.
Zurück zum Zitat Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; 33: 911–28PubMed Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; 33: 911–28PubMed
30.
Zurück zum Zitat Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897–906PubMedCrossRef Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897–906PubMedCrossRef
31.
Zurück zum Zitat Van Doorslaer EKA. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis. Dermatology 1996; 193: 239–44PubMedCrossRef Van Doorslaer EKA. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis. Dermatology 1996; 193: 239–44PubMedCrossRef
32.
Zurück zum Zitat Sculpher M, Michaels J, McKenna M, et al. Acost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104–25PubMedCrossRef Sculpher M, Michaels J, McKenna M, et al. Acost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104–25PubMedCrossRef
33.
Zurück zum Zitat Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247–57PubMedCrossRef Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247–57PubMedCrossRef
34.
Zurück zum Zitat Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789–96PubMedCrossRef Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789–96PubMedCrossRef
35.
Zurück zum Zitat Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64–76PubMed Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64–76PubMed
36.
Zurück zum Zitat Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–8PubMedCrossRef Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–8PubMedCrossRef
37.
Zurück zum Zitat Dowie J. Evidence-based, cost-effective and preference-driven medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1996; 1: 104–13PubMed Dowie J. Evidence-based, cost-effective and preference-driven medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1996; 1: 104–13PubMed
38.
Zurück zum Zitat Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. Centre for Health Economics (CHE) discussion paper. York: CHE, University of York. In press Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. Centre for Health Economics (CHE) discussion paper. York: CHE, University of York. In press
39.
Zurück zum Zitat Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104PubMedCrossRef Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104PubMedCrossRef
40.
Zurück zum Zitat Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996; 24: 1008–34CrossRef Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996; 24: 1008–34CrossRef
41.
Zurück zum Zitat Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992; 12: 53–63PubMedCrossRef Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992; 12: 53–63PubMedCrossRef
42.
Zurück zum Zitat Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means. Med Decis Making 1997; 17: 483–9PubMedCrossRef Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means. Med Decis Making 1997; 17: 483–9PubMedCrossRef
43.
Zurück zum Zitat Tosteson ANA, Rosenthal DI, Melton J, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed Tosteson ANA, Rosenthal DI, Melton J, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed
44.
Zurück zum Zitat Briggs A, Sculpher M, Britton A, et al. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assess Health Care 1998; 14 (4): 743–61PubMedCrossRef Briggs A, Sculpher M, Britton A, et al. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assess Health Care 1998; 14 (4): 743–61PubMedCrossRef
Metadaten
Titel
Assessing Quality in Decision Analytic Cost-Effectiveness Models
A Suggested Framework and Example of Application
verfasst von
Dr Mark Sculpher
Elisabeth Fenwick
Karl Claxton
Publikationsdatum
01.05.2000
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 5/2000
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200017050-00005

Weitere Artikel der Ausgabe 5/2000

PharmacoEconomics 5/2000 Zur Ausgabe

Consensus Conference Papers

Modelling in Health Economic Evaluation

Adis Pharmacoeconomic Drug Evaluation

Mirtazapine